To the Editor Discussions around the diagnosis, treatment, and outcomes after a diagnosis of ductal carcinoma in situ (DCIS) continue to generate great interest. Narod and colleagues1 confirm findings from other studies that have repeatedly shown a low breast cancer–specific mortality following a diagnosis of DCIS (3.3% at 20 years) and support the need to reconsider the management of DCIS.
Fallowfield L, Francis A, Thompson AM. Effects of Standard Treatments for Ductal Carcinoma In Situ—Making Informed Choices. JAMA Oncol. 2016;2(3):396–397. doi:10.1001/jamaoncol.2015.4857
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: